# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
SLXN: 50% | Silexion Highlights Preclinical Data Of SIL204 Supporting Dual-Route Treatment Strategy With Phase 2/3 Trial On Tra...
Amesite Inc. (NASDAQ:AMST), a leading developer of AI-powered enterprise solutions, today announced 63% revenue growth for its ...
Amesite Inc. (NASDAQ:AMST), a leading developer of AI-powered enterprise solutions, today announced the launch of the new Nurse...
Amesite Inc. (NASDAQ:AMST), a leading developer of AI-powered enterprise solutions, today announced that its flagship app, Nurs...
https://patentcenter.uspto.gov/applications/18176303/ifw/docs